Skip to main content
SpringerLink
Log in
Book cover

Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract pp 141–154Cite as

Clinical Management of Targeted Therapies in Neuroendocrine Tumours

  • Chapter
  • First Online:

  • 1273 Accesses

Abstract

Targeted treatments such as sunitinib and everolimus are providing exciting new options for the management of pancreatic neuroendocrine tumours (pNETs). Clinical management of patients receiving targeted therapies aims to maximise the benefits patients achieve whilst minimising the impact of side effects to maintain quality of life. Adverse event management requires physicians to control co-morbidities, carefully review medication histories and to educate and support patients prior to receiving new treatments. Individual strategies to control specific common side effects such as fatigue, diarrhoea and stomatitis should be employed to allow optimal treatment duration and maintenance of dose intensity; all of which are key to ensure maximum benefit is derived from any treatment option. Recognising and acknowledging the difficulties patients may experience with adherence to chronic medications, and providing strategies to overcome them is a further important component of patient care. At the core of clinical management is effective communication between patients and physicians, which ensures patients are fully involved in decisions concerning their care, and will allow advances in the use of targeted therapies to be translated into benefits for individual patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Yao JC et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

    Article  PubMed  Google Scholar 

  2. Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513

    Article  CAS  PubMed  Google Scholar 

  3. Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523

    Article  CAS  PubMed  Google Scholar 

  4. Pavel ME et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012

    Article  CAS  PubMed  Google Scholar 

  5. Hubner RA, Valle JW (2011) Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 11(12):1817–1827

    Google Scholar 

  6. Gore ME et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757–763

    Article  CAS  PubMed  Google Scholar 

  7. Porta C et al (2008) Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. In: ASCO meeting abstract

    Google Scholar 

  8. Schwandt A et al (2009) Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther 2:51–61

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Negrier S, Ravaud A (2007) Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer 5(7):12–19

    Article  CAS  Google Scholar 

  10. Rock EP et al (2007) Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12(1):107–113

    CAS  PubMed  Google Scholar 

  11. Brock MV et al (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358(11):1118–1128

    Article  CAS  PubMed  Google Scholar 

  12. Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl 2):32–44

    Article  PubMed Central  PubMed  Google Scholar 

  13. Oberstein PE, Saif MW (2012) Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 6:41–51

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Bhojani N et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53(5):917–930

    CAS  PubMed  Google Scholar 

  15. Ravaud A (2009) How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 20(Suppl 1):i7–i12

    Article  PubMed  Google Scholar 

  16. Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 12(9):626–633

    PubMed  Google Scholar 

  17. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73(2):156–166

    Article  PubMed  Google Scholar 

  18. Schmidinger M et al (2010) Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 28(8):856–864

    Article  CAS  PubMed  Google Scholar 

  19. Eisen T et al (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104(2):93–113

    CAS  PubMed  Google Scholar 

  20. O’Brien BE, Kaklamani VG, Benson AB 3rd (2005) The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer 4(6):375–381 (discussion 382–383)

    Google Scholar 

  21. Degen A et al (2010) The hand-foot-syndrome associated with medical tumor therapy: classification and management. J Dtsch Dermatol Ges 8(9):652–661

    PubMed  Google Scholar 

  22. Porta C, Szczylik C (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 35(3):297–307

    Article  CAS  PubMed  Google Scholar 

  23. Rini BI et al (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1):81–83

    CAS  PubMed  Google Scholar 

  24. Beaumont JL et al (2012) Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3):461–466

    Article  CAS  PubMed  Google Scholar 

  25. Raymond E et al (2010) Evidence of activity and clinical benefit with sunitinib in patients with pancreatic neuroendocrine tumours. In: 12th World congress on gastrointestinal cancer. Barcelona, Spain

    Google Scholar 

  26. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304(1):10–15

    Article  CAS  PubMed  Google Scholar 

  27. Houk BE et al (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357–371

    Article  CAS  PubMed  Google Scholar 

  28. Negrier S (2012) Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices. Oncology 82(4):189–196

    Article  PubMed  Google Scholar 

  29. Le Tourneau C et al (2012) Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents. Br J Cancer 106(5):854–857

    Article  PubMed Central  PubMed  Google Scholar 

  30. Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661

    Article  PubMed  Google Scholar 

  31. Andrade SE et al (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–574 (discussion 575–577)

    Google Scholar 

  32. Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606

    Article  CAS  PubMed  Google Scholar 

  33. Levine AM et al (1987) Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 5(9):1469–1476

    CAS  PubMed  Google Scholar 

  34. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497

    Article  CAS  PubMed  Google Scholar 

  35. Wang PS et al (2002) Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 17(7):504–511

    Article  PubMed Central  PubMed  Google Scholar 

  36. Love RR et al (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151(9):1842–1847

    Article  CAS  PubMed  Google Scholar 

  37. Pollak KI et al (2007) Oncologist communication about emotion during visits with patients with advanced cancer. J Clin Oncol 25(36):5748–5752

    Article  PubMed  Google Scholar 

  38. Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288(22):2880–2883

    Article  PubMed  Google Scholar 

  39. Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60(9):869–875

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Arnold-Worner N et al (2008) The importance of specialist treatment, treatment satisfaction and diabetes education for the compliance of subjects with type 2 diabetes: results from a population-based survey. Exp Clin Endocrinol Diab 116(2):123–128

    Article  CAS  Google Scholar 

  41. Haynes RB et al (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002(2):CD000011

    Google Scholar 

  42. Roter DL et al (1998) Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 36(8):1138–1161

    Article  CAS  PubMed  Google Scholar 

  43. Bitar R et al (2004) Does tumor status influence cancer patients’ satisfaction with the doctor-patient interaction? Support Care Cancer 12(1):34–40

    Article  PubMed  Google Scholar 

  44. Greenfield S, Kaplan S, Ware JE Jr (1985) Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 102(4):520–528

    Article  CAS  PubMed  Google Scholar 

  45. Baile WF, Aaron J (2005) Patient-physician communication in oncology: past, present, and future. Curr Opin Oncol 17(4):331–335

    Article  PubMed  Google Scholar 

  46. Bredart A, Bouleuc C, Dolbeault S (2005) Doctor-patient communication and satisfaction with care in oncology. Curr Opin Oncol 17(4):351–354

    Article  PubMed  Google Scholar 

  47. Fallowfield L et al (2003) Enduring impact of communication skills training: results of a 12-month follow-up. Br J Cancer 89(8):1445–1449

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK

    L. Carter, R. A. Hubner & J. W. Valle

  2. School of Cancer and Enabling Sciences, The University of Manchester, Manchester, UK

    J. W. Valle

Authors
  1. L. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. A. Hubner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. W. Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. W. Valle .

Editor information

Editors and Affiliations

  1. Medical Oncology, Bichat-Beaujon University Hospitals, Clichy cedex, France

    Eric Raymond

  2. Bichat-Beaujon University Hospitals Medical Oncology, Clichy cedex, France

    Sandrine Faivre

  3. Pancreatology, Bichat-Beaujon University Hospitals Gastroenterology and, Clichy cedex, France

    Philippe Ruszniewski

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag France

About this chapter

Cite this chapter

Carter, L., Hubner, R.A., Valle, J.W. (2014). Clinical Management of Targeted Therapies in Neuroendocrine Tumours. In: Raymond, E., Faivre, S., Ruszniewski, P. (eds) Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract. Springer, Paris. https://doi.org/10.1007/978-2-8178-0430-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0430-9_10

  • Published:

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0429-3

  • Online ISBN: 978-2-8178-0430-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation